abstract: BACKGROUND: Epidemic @entity24231 is a highly contagious @entity2194 that occurs worldwide and is caused mainly by adenoviruses and enteroviruses. An 18-year analysis of the changes of pathogens and clinical signs in a subtropical and densely populated island presents certain special features. METHODS: We retrospectively analyzed the clinical information and laboratory records of the @entity2024 @entity1 with positive conjunctival swabs from 1980 to 1997. RESULTS: The positive rate of laboratory diagnosis of @entity2024 was 50.0% (1,233/2,467). From 1980 to 1994, the predominant causative agent of @entity9849 was adenovirus type 8 (Ad8), with six genotypes being evolved. Three of the new Ad8 genotypes each caused a new epidemic. After 1995 the predominant adenoviral pathogens shifted to Ad37 and @entity43664 , and no more Ad8 was isolated. Enterovirus type 70 (EV70) was isolated from four outbreaks of @entity5518 ( @entity5518 ) from 1980 to 1984, but rarely in later years. @entity14590 type 24 variant (CA24v), which first appeared in 1985, appeared later as the causes of four major epidemics of @entity5518 from 1985 to 1994. The overall clinical symptoms of @entity24231 were more severe in the 1990s than in the 1980s. CONCLUSION: In southern Taiwan, outbreaks of @entity9849 caused by new genomic variants could be associated with the long-term endemic co-circulation of Ad8, @entity43664 , and Ad37, while epidemics of CA24v @entity5518 were caused mainly by introduction of new viral strains from neighboring countries. The aggravation of host symptoms in the 1990s needs further investigation and close follow-up.

title: The change of etiological agents and clinical signs of XXXX over an 18-year period in southern Taiwan.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2194 :: ('MESH:D005128', 'Disease') :: ['eye disease']

entities_list: @entity14590 :: ('138948', 'Species') :: ['Coxsackievirus A']

entities_list: @entity9849 :: ('MESH:D007637', 'Disease') :: ['adenoviral keratoconjunctivitis']

entities_list: @entity5518 :: ('MESH:D003232', 'Disease') :: ['AHC', 'acute hemorrhagic conjunctivitis']

entities_list: @entity24231 :: ('MESH:D003236', 'Disease') :: ['viral conjunctivitis']

entities_list: @entity2024 :: ('MESH:D003231', 'Disease') :: ['conjunctivitis', 'epidemic conjunctivitis']

answer: @entity24231 :: (MESH:D003236,Disease) :: ['epidemic viral conjunctivitis']


abstract: BACKGROUND: Mobile technology enables high frequency mood monitoring and automated passive collection of data (e.g. actigraphy) from @entity1 more efficiently and less intrusively than has previously been possible. Such techniques are increasingly being deployed in research and clinical settings however little is known about how such approaches are experienced by @entity1 . Here, we explored the experiences of individuals with @entity162 engaging in a study involving mood and activity monitoring with a range of portable and wearable technologies. METHOD: @entity1 were recruited from a wider sample of 50  individuals with @entity162 taking part in the Automated Monitoring of Symptom Severity (AMoSS) study in Oxford. A sub-set of 21  @entity1 participated in a qualitative interview that followed a semi-structured approach. RESULTS: Monitoring was associated with benefits including @entity101 insight, behavioural change. Concerns were raised about the potential preoccupation with, and @entity10963 about, monitoring. @entity1 emphasized the need for personalization, flexibility, and the importance of context, when monitoring mood. CONCLUSIONS: Mobile and electronic health approaches have potential to lend new insights into mental health and transform healthcare. Capitalizing on the perceived utility of these approaches from the @entity1 ' perspective, while addressing their concerns, will be essential for the promise of new technologies to be realised.

title: Experiences of remote mood and activity monitoring in XXXX : A qualitative study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity162 :: ('MESH:D001714', 'Disease') :: ['bipolar disorder', 'Bipolar Disorder']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['increased illness']

answer: @entity162 :: (MESH:D001714,Disease) :: ['bipolar disorder']


abstract: Intracellular @entity141 was determined with the @entity593 technique during electrically induced contractions in the @entity95 rectococcygeus smooth muscle at 22 degreesC. The muscles were electrically activated to give short, reproducible contractions. Intracellular [ @entity141 ] increased during activation; the increase in [ @entity141 ] preceded force development by approximately 2 s. After cessation of stimulation @entity141 fell, preceding the fall in force by approximately 4 s. The fluorescence properties of @entity593 were determined with time-resolved spectroscopy using synchrotron light at the MAX-storage ring, Lund, Sweden. The fluorescence decay of free @entity593 was best described by two exponential decays (time constants approximately 0.5 and 1.5 ns) at low @entity141 (pCa 9). At high @entity141 (pCa 4.5), fluorescence decay became slower and could be fitted by one exponential decay (1.9 ns). Time-resolved anisotropy of free @entity593 was characteristic of free rotational motion (correlation time 0.3 ns). Motion of @entity593 could be markedly inhibited by high concentrations of @entity908 kinase. Time-resolved spectroscopy measurements of muscle fibers loaded with @entity593 showed that the fluorescence lifetime of the probe was longer, suggesting an influence of the chemical environment. Anisotropy measurements revealed, however, that the probe was mobile in the cells. The @entity141 -dependence of contraction and relaxation was studied using a photolabile @entity460 chelator, @entity54670 , which could be loaded into the muscle cells in a similar manner as @entity593 . Photolysis of @entity54670 leads to an increase in its @entity141 -affinity and a fall in free @entity141 . When muscles that had been loaded with @entity54670 were illuminated with UV light flashes during the rising phase of contraction, the rate of contraction became slower, suggesting a close relation between intracellular @entity141 and the cross-bridge interaction. In contrast, photolysis during relaxation did not influence the rate of force decay, suggesting that relaxation of these contractions is not determined by the rate of @entity141 removal or due to an increased @entity141 sensitivity, but instead is limited by other processes such as deactivation by dephosphorylation or detachment of tension-bearing cross-bridges, possibly regulated by thin filament systems.

title: @entity460 transients and the effect of a photolytically released @entity460 chelator during electrically induced contractions in XXXX rectococcygeus smooth muscle.

entities_list: @entity908 :: ('MESH:D003401', 'Chemical') :: ['creatine']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

answer: @entity95 :: (9986,Species) :: ['rabbit']


abstract: BACKGROUND: @entity566 arise from aberrant @entity61 responses to allergens. The processes involved in the genesis of @entity56 sensitization remain elusive. Some allergens such as derived from house dust mites have proteolytic activity which can induce oxidative stress in vivo. A reduced capacity of the host to control oxidative stress might prime for @entity56 sensitization. METHODS: Two different strains of @entity19 were compared for their antioxidant and immune response to HDM. Protease activity of the HDM extract was reduced to investigate its role in oxidative stress induction in the airways and whether this induction could determine @entity56 sensitization and @entity32 . The role of oxidative stress in @entity56 sensitization was also investigated in @entity1 . An occupational cohort of animal workers was followed for the development of sensitization to rodent urinary proteins. Levels of oxidative stress in serum and antioxidant responses by PBMCs were determined. RESULTS: Susceptibility to @entity56 sensitization to mite allergens in @entity19 was highly dependent on host genetic background and was associated with oxidative stress in the lungs before allergen exposure and poor antioxidant response after allergen exposure. Reduction in mite protease activity limited its capacity to induce oxidative stress and @entity32 in @entity19 . We showed that also in @entity1 subjects, oxidative stress before allergen exposure and poor antioxidant responses were associated with predisposition to occupational @entity566 . CONCLUSION: Our study indicates that oxidative stress condition before allergen exposure due to an inadequate antioxidant response may prime for @entity56 @entity61 responses.

title: Allergic sensitization is associated with inadequate antioxidant responses in @entity19 and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['humans', 'human']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation', 'allergic inflammation']

entities_list: @entity566 :: ('MESH:D006967', 'Disease') :: ['allergy', 'Allergies']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic']

answer: @entity1 :: (9606,Species) :: ['men']


abstract: BACKGROUND: @entity1 with @entity6 ( @entity6 ) and @entity209 are at increased risk of @entity301 ( @entity301 ). Studies have shown differential statin efficacy on low-density lipid @entity165 ( @entity11429 ) by @entity301 risk strata. OBJECTIVE: The aim of this study was to evaluate the consistency of effect with @entity3709 / @entity3413 (E/S) combination therapy, @entity2993 , or @entity8671 in @entity1 with @entity6 , @entity209 , or neither condition (No @entity6 / @entity209 ), stratified by the National @entity165 Education Panel Adult Treatment Panel III (NCEP ATP III) @entity301 risk group. METHODS: Post hoc analyses of 2 multicenter, double-blind, randomized, 6-week studies comparing E/S 10/10, 10/20, 10/40, or 10/80 mg with either @entity2993 10, 20, 40, or 80 mg, or @entity8671 10, 20, or 40 mg. Treatments were compared by pooling across all doses for @entity11429 reduction and NCEP @entity11429 goal attainment in @entity1 with @entity6 , @entity209 without @entity6 , or No @entity6 / @entity209 across NCEP @entity301 risk strata. RESULTS: NCEP @entity11429 goal attainment was lowest in the high-risk group with @entity731 (12-64%) and greatest in the moderate and low-risk groups (84-100%). In contrast, @entity11429 reduction was generally similar irrespective of disease or risk subgroup. All treatments were generally well tolerated, with overall similar safety regardless of disease and risk level. CONCLUSIONS: In these studies, @entity301 risk strata were inversely related to the likelihood of attaining NCEP @entity11429 goals, but did not appear to affect the percentage @entity11429 change from baseline. This demonstrates the need for especially aggressive @entity165 lowering necessary to reach the lower @entity11429 goal for high-risk @entity1 .

title: Low-density lipoprotein @entity165 reduction and goal achievement with @entity3709 / @entity3413 versus @entity2993 or @entity8671 in @entity1 with XXXX , @entity209 , or neither disease, stratified by National @entity165 Education Program risk category.

entities_list: @entity3413 :: ('MESH:D019821', 'Chemical') :: ['simvastatin']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus', 'DM']

entities_list: @entity301 :: ('MESH:D003327', 'Disease') :: ['CHD', 'coronary heart disease']

entities_list: @entity2993 :: ('MESH:C065179', 'Chemical') :: ['atorvastatin']

entities_list: @entity8671 :: ('MESH:C422923', 'Chemical') :: ['rosuvastatin']

entities_list: @entity3709 :: ('MESH:C108606', 'Chemical') :: ['ezetimibe']

entities_list: @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic syndrome']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic vascular disease']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['Cholesterol', 'cholesterol']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetes']


abstract: The incidence of the EGJA is rapidly increasing. The clinicopathological features have not yet been elucidated. The aim of this study was to analyze the differences in clinicopathological features and prognosis between @entity1 with esophagogastric junctional @entity420 (EGJA) and distal @entity356 (DGA).In this retrospective study, 1230 @entity1 who underwent gastrectomy between January 2006 and December 2010 in West China Hospital were enrolled. @entity1 were divided into 2 groups based on @entity5 location. Clinicopathological characteristics, @entity260 , and survival outcomes were compared. Univariate and multivariate analysis were also used to evaluate the prognostic factors of DGA and EGJA. @entity1 with @entity356 were divided into 2 study groups according to @entity5 location: 321 EGJA (26.1%) and 909 DGA (73.9%). Tumors with larger diameter, more advanced pT and pN stage were more common in EGJA. Significant differences were revealed in 3-year overall survival rate (3-YS) between 2 groups: EGJA (57.5%) and DGA (65.5%) (P=0.001), and further analysis indicate that there was also significant difference on 3-YS between EGJA (76.9%) and DGA (84.2%) (P=0.012) in stage II. From our multivariate analysis, we found that there were different independent prognostic indicators for DGA and EGJA.The clinicopathological features of EGJA were strikingly different from DGA and @entity1 with EGJA showed a worse prognosis when compared with DGA. The pT stage, pN stage, pM stage, @entity5 size, age, and radical degree were determined to be independent factors of prognosis for DGA, while only combined organ resection, pN stage, and pM stage were independent prognostic factors for EGJA.

title: Comparison on Clinicopathological Features and Prognosis Between Esophagogastric Junctional @entity420 (Siewert II/III Types) and Distal XXXX : Retrospective Cohort Study, a Single Institution, High Volume Experience in China.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['postoperative complications']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric adenocarcinoma']

answer: @entity356 :: (MESH:D013274,Disease) :: ['Gastric Adenocarcinoma']


abstract: Introduction. @entity9718 ( @entity9718 ) is a rare @entity74 that primarily involves progressive @entity508 of the legs (hamstrings, quadriceps, and @entity291 ). Methods. A 27-year-old gentleman was a fast runner and able to play soccer until age 9 when he developed slowly progressive @entity425 . He was wheelchair-bound by age 25. He was evaluated by laboratory testing, imaging, electrodiagnostics, and molecular genetics. Results. Electrodiagnostic testing revealed an @entity39097 . Genetic testing for @entity9718 in 2003 was negative; repeat testing in 2013 revealed a mutation in @entity63241 ( @entity69780 ; @entity63244 ). Conclusions. A recent advance in neurogenetics has allowed for more genes and mutations to be identified; over 76 different genetic loci for @entity9718 and 59 gene products are currently known. Even though our @entity1 had a sensorimotor @entity305 on electrodiagnostic testing and a 2003 @entity9718 genetic panel that was negative, a repeat @entity9718 genetic panel was performed in 2013 due to the advancement in neurogenetics. This revealed a mutation in @entity63241 .

title: Progressive Lower Extremity Weakness and @entity39097 from a Mutation in @entity63241 ( XXXX ; @entity63244 ).

entities_list: @entity9718 :: ('MESH:D015419', 'Disease') :: ['Hereditary Spastic Paraplegia', 'HSP']

entities_list: @entity508 :: ('MESH:D009128', 'Disease') :: ['spasticity']

entities_list: @entity305 :: ('MESH:D011115', 'Disease') :: ['polyneuropathy']

entities_list: @entity425 :: ('MESH:D018908', 'Disease') :: ['weakness']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['hereditary disorder']

entities_list: @entity39097 :: ('MESH:C565773', 'Disease') :: ['axonal sensorimotor polyneuropathy']

entities_list: @entity63244 :: ('p|SUB|R|204|Q', 'ProteinMutation') :: ['p.Arg204Gln']

answer: @entity69780 :: (c|SUB|G|611|A,DNAMutation) :: ['c.611G>A']


abstract: BACKGROUND: @entity1636 ( @entity1636 ) is a rare but lethal malignancy with few reliable prognostic markers. FDG-PET metabolic parameters have been shown to predict survival in several @entity5 . The objective was to determine if metabolic @entity5 volume (MTV), total lesion glycolysis (TLG), and maximum standardized uptake value (SUVmax) could serve as prognostic markers in @entity1 with @entity1636 . METHODS: A total of 30 @entity1 with @entity1636 prospectively underwent 18F-FDG PET/CT prior to treatment. Whole body MTV, TLG, and SUVmax were measured by a semiautomatic method. A median cutoff was used to determine an association with @entity1349 ( @entity1349 ) from the time of 18F-FDG PET/CT by the Kaplan-Meier method. RESULTS: @entity1 with high whole body MTV (>87.0 mL),TLG (>229.4 SUVlbm*mL), or SUVmax (>8.9 SUV) had a worse @entity1349 compared with those with low whole body MTV (median @entity1349 , 24 vs 45.1 months, p < .01), TLG (median @entity1349 , 24 vs 40.3 months, p < .005), or SUVmax (median @entity1349 , 23.7 vs 35.5 months, p < .02). In @entity1 who had operable disease (n = 23), high whole body MTV (>87.0 mL) and TLG (>229.4 SUVlbm*mL) had a worse @entity1349 compared with those with low whole body MTV (median @entity1349 , 25.1 vs 45.1 months, p < .05) and TLG (median @entity1349 , 25.1 vs 40.3 months, p < .05), but a high SUVmax (>8.9 SUV) was not associated with worse @entity1349 (p = .11). CONCLUSIONS: @entity1 with @entity1636 and a high whole body MTV, TLG, and SUVmax have a worse prognosis and @entity1349 . Measurement of whole body MTV and TLG may be helpful for guiding therapy for @entity1 with @entity1636 .

title: Whole Body Metabolic Tumor Volume and Total Lesion Glycolysis Predict Survival in @entity1 with XXXX .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers']

entities_list: @entity1636 :: ('MESH:D018268', 'Disease') :: ['Adrenocortical carcinoma', 'ACC']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity1636 :: (MESH:D018268,Disease) :: ['Adrenocortical Carcinoma']


abstract: AIMS: @entity1555 are @entity1112 associated with both skeletal @entity121 and progressive @entity296 in males. Female @entity1555 / @entity1555 carriers (DMDc/BMDc) are mostly free of skeletal muscle symptoms, but they are also prone to @entity296 . The aim of the current study was to characterize the frequency, pattern, and extent of @entity296 in female @entity1555 / @entity1555 carriers (DMDc/BMDc) in comparison to their first-degree male @entity601 relatives. METHODS AND RESULTS: Thirty-six (age 44    14 years) female @entity601 carriers (20 DMDc and 16 BMDc) constituted the ' @entity601 carrier group' and were prospectively enrolled. All @entity601 carriers underwent a complete CMR study comprising cine- and late @entity2287 enhancement (LGE) imaging. In 22 of these @entity1 ('female @entity601 carrier comparison group', 7 @entity1555 and 15 @entity1555 ), at least one first-degree male relative with a previously established diagnosis of @entity601 underwent the same CMR protocol and was assigned to the 'male @entity601 comparison group' (n = 24, 6 @entity1555 and 18 @entity1555 ). In the total @entity601 carrier group, 17 (47%) @entity601 carriers had at least one pathological CMR finding [5 (14%) with a reduced left ventricular ejection fraction (LV-EF) and 16 (44%) with the presence of LGE]. All LGE-positive @entity1 (n = 16) showed non-ischaemic LGE with subepicardial involvement of the LV lateral free wall being the most frequent pattern (13/16, 81%). Compared with BMDc, DMDc demonstrated more frequently a pathological CMR result (65 vs. 19%; P = 0.008)-in spite of being significantly younger (40    11 vs. 50    16 years, P = 0.038). In the male @entity601 comparison group, the same LGE pattern as in female carriers was seen, but with a significantly higher prevalence of @entity299 compared with their female carrier relatives constituting the female @entity601 comparison group (75 vs. 27%; P = 0.003). CONCLUSION: Cardiac involvement is a frequent finding in female carriers of @entity1555 , but less frequently observed in carriers of @entity1555 . Those DMDc and BMDc with cardiac involvement demonstrate the same @entity296 pattern as their male counterparts with overt disease.

title: Cardiac involvement in female XXXX carriers in comparison to their first-degree male relatives: a comparative cardiovascular magnetic resonance study.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['cardiomyopathy', 'myocardial fibrosis']

entities_list: @entity1112 :: ('MESH:D040181', 'Disease') :: ['X-linked recessive disorders']

entities_list: @entity1555 :: ('MESH:D020388', 'Disease') :: ['BMD', 'Duchenne (DMD) and Becker (BMD) muscular dystrophies', 'DMD']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac abnormalities']

entities_list: @entity2287 :: ('MESH:D005682', 'Chemical') :: ['gadolinium']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['myopathy']

answer: @entity1555 :: (MESH:D020388,Disease) :: ['Duchenne and Becker muscular dystrophy']


abstract: OBJECTIVES: We compared a strategy of tenecteplase (TNK)-facilitated angioplasty with one of TNK alone in @entity1 presenting with high-risk @entity583 ( @entity583 ). BACKGROUND: Previous trials show that thrombolysis followed by immediate angioplasty for the treatment of @entity583 does not improve @entity63 outcomes compared with thrombolysis alone and is associated with excessive @entity548 complications. Since the publication of these trials, however, significant pharmacological and technological advances have occurred. METHODS: We randomized 170 @entity1 with high-risk @entity583 to treatment with TNK alone (84 @entity1 ) or TNK-facilitated angioplasty (86 @entity1 ). The primary end point was a composite of @entity204 , reinfarction, recurrent unstable @entity63 , or @entity64 at six months. RESULTS: At six months, the incidence of the primary end point was 24.4% in the TNK-alone group versus 11.6% in the TNK-facilitated angioplasty group (p = 0.04). This difference was driven by a reduction in the rate of recurrent unstable @entity63 (20.7% vs. 8.1%, p = 0.03). There was a trend toward a lower reinfarction rate with TNK-facilitated angioplasty (14.6% vs. 5.8%, p = 0.07). No significant differences were observed in the rates of @entity204 or @entity64 . Major @entity548 was observed in 7.1% of the TNK-alone group and in 8.1% of the TNK-facilitated angioplasty group (p = 1.00). CONCLUSIONS: In @entity1 presenting with high-risk @entity583 , TNK plus immediate angioplasty reduced the risk of recurrent @entity63 events compared with TNK alone and was not associated with an increase in major @entity548 complications.

title: Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute XXXX (CAPITAL AMI study).

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia', 'ischemic']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['STEMI', 'ST-segment elevation myocardial infarction']

answer: @entity583 :: (MESH:D009203,Disease) :: ['myocardial infarction']


abstract: INTRODUCTION: Susceptibility to @entity11535 ( @entity11535 ) is known to be affected by gender and ethnic origin, but whether gender and ethnicity are interacting is unknown. METHODS: We investigated @entity11535 development in healthy Caucasian subjects (n = 227), and in subjects of Chinese origin (n = 82). All subjects were exposed to @entity390 -inducing @entity717 in a rotation chair, and rotated around the yaw axis for 5 x 1 min, while they were instructed to move their heads. Prior to rotation, subjects had to fill out a motion- @entity2704 susceptibility questionnaire (MSSQ). Total @entity717 ( @entity717 ) was noted. Symptom ratings (SR) were performed at the beginning, and immediately after the end of each rotation, and 15 and 30 min later. RESULTS: The average @entity717 was significantly higher in Caucasian (163 +/- 6 s) than in Chinese subjects (111 +/- 7 s) (F = 24.84, p < 0.0001). The adult MSSQ score was significantly lower in Caucasians (17.8 +/- 1.1) than in Chinese volunteers (24.2 +/- 2.1) (F = 6.05, p = 0.014). Maximal SR post rotation was similar in Chinese and Caucasian subjects. @entity717 was highly predictable from the MSSQ scores, but separate for both genders. CONCLUSION: Susceptibility to @entity11535 is affected by both ethnic origin and by gender in a rather complex fashion. The most reliable prediction of @entity717 can be based on the individual's history as assessed by the MSSQ.

title: Effects of ethnicity and gender on XXXX susceptibility.

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['RT', 'rotation tolerance time', 'body rotations']

entities_list: @entity11535 :: ('MESH:D009041', 'Disease') :: ['motion sickness', 'MS']

answer: @entity11535 :: (MESH:D009041,Disease) :: ['motion sickness']


abstract: We report clinical and neuroimaging findings for three @entity1 suffering from @entity195 ( @entity195 ) with focal motor symptoms. These @entity1 initially showed @entity73 and subsequently featured myoclonus and awkward movements in the unilateral upper limb while progressing to paresis. Paresis was noted in the unilateral upper limb. All @entity1 held the unilateral arm flexed at the wrist and elbow, closely adducted to the body and the hand fisted and pronated. No signs of @entity6447 , @entity132 or long tract signs were observed, nor any of the initial non-cognitive behavioural changes typical of @entity4943 . EEGs of these @entity1 showed marked slowing of basic activity without @entity302 discharges. MRIs showed progressive @entity1010 in the contralateral frontoparietal lobes as well as the hippocampal formation. Cases 2 and 3 featured extensive long T2 lesions on MRI. 99mTc-HMPAO-SPECT revealed blood flow hypoperfusion in the corresponding regions. The cerebellum and brain stem showed neither @entity154 nor blood flow hypoperfusion. On the basis of these clinical and neuroimaging observations, the focal motor symptoms were attributed to contralateral frontoparietal cortical @entity194 with or without @entity62 .

title: Report of three cases of XXXX with focal motor symptoms: clinical correlates of neuroimaging findings.

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['morphological abnormalities']

entities_list: @entity132 :: ('MESH:D010468', 'Disease') :: ['sensory disturbance']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive deficits']

entities_list: @entity1010 :: ('MESH:C566985', 'Disease') :: ['brain atrophy']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epileptic']

entities_list: @entity6447 :: ('MESH:D002524', 'Disease') :: ['cerebellar ataxia']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ['AD', "Alzheimer's disease"]

entities_list: @entity4943 :: ('MESH:D057180', 'Disease') :: ['frontotemporal dementia']

entities_list: @entity62 :: ('MESH:D056784', 'Disease') :: ['white matter lesion']

answer: @entity195 :: (MESH:D000544,Disease) :: ['Alzheimer's disease']


abstract: INTRODUCTION: @entity1593 ( @entity1593 ) is an autoimmunological @entity1593 occuring to genetically predisposed individuals. Active @entity1593 is accompanied by presence of multiple antibodies. Anti alpha enolase antibodies were reported in @entity146 like @entity309 , @entity991 . Data about its presence and role in @entity1593 is avaricious. AIM: The aim of this study was to determine presence of anti alpha enolase antibodies in @entity1593 , correlation with gluten exposure, presence of anti tranglutaminase antibodies and Marsh scale. METHODS: Sera from 31 @entity1 with @entity1593 (21 females, 10 males) and 6 healthy subjects were collected. Evaluation of @entity1593 activity and adherence to gluten free diet were obtained by serology tests (presence of endomyslum antibodies and/or anti transglutamineses in IgA or IgG classes) and histological hallmarks. Anti alpha enolase antibodies were identified in sera using ELISA kit. Titres of anti alpha enolase antibodies were identified among @entity1 with newly diagnosed @entity1593 , @entity1593 @entity1 non adhering to gluten free diet (GFD), adhering to GFD and among healthy subjects. RESULTS: Mean titre of anti alpha enolase antibodies was higher in @entity1593 @entity1 (both treated and non treated) in comparison to control group, respectively 1.1 ng/mL, and 0.795 ngl mL. Among @entity1593 @entity1 non adhering to gluten free diet mean titre was 1.4 ng/mL. CONCLUSIONS: Higher anti alpha enolase antibodies titres in non treated @entity1593 suggest usefulness of its measurement. These antibodies might be a novel marker of @entity32 among @entity1593 @entity1 non adhering to GFD.

title: [Antibodies against alfa-enolase as an indication of inflammatory process in XXXX with celiac disease--preliminary results].

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['chronic inflammation']

entities_list: @entity1593 :: ('MESH:D002446', 'Disease') :: ['Celiac disease', 'CD', 'gluten sensitive enteropathy']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['several autoimmunological disorders']

entities_list: @entity991 :: ('MESH:D015209', 'Disease') :: ['primary sclerosing cholangitis']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: Repair of a @entity397 is a challenging procedure and, to date, there is no consensus as to which technique should be used because of the specific complications reported for each. PURPOSE: A new endoscopic technique is described that uses a suture anchor to repair distal biceps tendon @entity397 . STUDY DESIGN: Case series; Level of evidence, 4. METHODS: The results of a cohort of 23 @entity1 (25 elbows) are reported with a median follow-up of 26 months. All @entity1 were male and their median age was 44 years (range, 30-58). Ten of the @entity1 (12 @entity397 ) were professional athletes or had a high level of physical activity. All repairs were performed via a 3-cm incision made in the "safe area" of the anterior crease of the forearm. The whole procedure was performed within the @entity1319 . The tendon was reinserted using a single anchor. RESULTS: Of the 23 @entity1 , 22 were satisfied and 20 @entity1 returned to their preinjury sports and jobs. There was a mean loss of 8.6 degrees of pronation and 5 degrees of supination. A single severe @entity16 , which required a second surgical procedure, was reported. There were also 2 ectopic ossifications without clinical consequences and a transitory radial nerve @entity912 . CONCLUSIONS: This study clearly demonstrated that endoscopic repair of the @entity397 is safe, effective, and reproducible. It provides good functional outcome and early recovery with few complications. Postoperative @entity10036 due to @entity4 is a possible concern for @entity1 involved in athletic activity and with a history of nerve entrapment; thus this technique should be used with caution in this group of @entity1 .

title: Repair of XXXX using a suture anchor: description of a new endoscopic procedure.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurologic complication']

entities_list: @entity10036 :: ('MESH:D020423', 'Disease') :: ['median nerve palsy']

entities_list: @entity397 :: ('MESH:D012421', 'Disease') :: ['ruptures', 'distal biceps tendon rupture', 'ruptured distal biceps tendon']

entities_list: @entity912 :: ('MESH:D010243', 'Disease') :: ['paralysis']

entities_list: @entity1319 :: ('MESH:D015835', 'Disease') :: ['tendon sheath']

answer: @entity397 :: (MESH:D012421,Disease) :: ['distal biceps tendon rupture']


abstract: BACKGROUND: RESULTS from previous studies concerning the association of @entity32688 @entity68170 polymorphism with risk of @entity5 were inconsistent. To explore the exact relation with susceptibility, we conducted the present meta-analysis. MATERIALS AND METHODS: Literature of electronic databases including PubMed, Web of Science, EMBASE, Wanfang and Chinese National Knowledge Infrastructure (CNKI) were systematically searched. ORs and their 95%CIs were used to assess the strength of associations between @entity32688 polymorphism and @entity5 risk. RESULTS: There was no significant association between @entity32688 @entity68170 AA or AG genotypes and overall risk of @entity5 (AA vs. GG: OR=0.998, 95%CI=0.670-1.486, P=0.992; AG vs. GG: OR=0.970, 95%CI=0.888- 1.061, P=0.508). A dominant genetic model also did not demonstrate significant association of (AA+AG) genotype carriers with altered risk of @entity5 (OR=0.985, 95%CI=0.909-1.068, P=0.719). In addition, no significant association was observed between A allele of @entity32688 @entity68170 @entity4866 polymorphism and altered @entity5 risk compared with G allele (OR=0.952, 95%CI=0.851-1.063, P=0.381). Subgroup analysis suggested that AA genotype carriers were significantly associated with decreased risk of @entity11 compared with wild-type GG genotype individuals (OR=0.523, 95%CI=0.275-0.993, P=0.048). For subgroup of @entity2 , A allele of @entity32688 @entity68170 @entity4866 polymorphism was significantly associated with decreased risk of @entity2 compared with G allele (OR=0.806, 95%CI=0.697-0.931, P=0.003). CONCLUSIONS: This meta-analysis indicated that @entity32688 @entity68170 @entity4866 polymorphism might not be associated with risk of @entity5 . However, individuals with the AA genotype were associated with significantly reduced risk of @entity11 compared with wild-type GG genotype; The A allele was associated with significantly reduced risk of @entity2 compared with G allele. Future large- scale studies performed in multiple populations are warranted to confirm our results.

title: Associations of @entity32688 XXXX Polymorphism with Cancer Risk: an Updated Meta-analysis.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['overall cancer', 'cancer']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer']

entities_list: @entity4866 :: ('c|SUB|A||G', 'DNAMutation') :: ['A/G']

answer: @entity68170 :: (rs1800067,SNP) :: ['rs1800067']


abstract: The assessment of @entity5 angiogenesis in @entity1149 is presently a subject of intensive research with potential clinical applications. In this study, the expression of @entity7 and @entity319 was examined by immunohistochemistry in 67 @entity5 samples obtained from @entity1149 @entity1 treated by radical resection. Distribution of age, sex, @entity5 stage and histology was typical for @entity1 population in Poland. @entity7 expression (more than 25% of positive cells) was noted in 65% of @entity5 cells. @entity319 expression was observed in 91% of @entity5 cells. Neither the number of positive cells nor the staining intensity correlated with the clinical variables (all p values >0.05, chi-square test). No correlation was noted between the expression of @entity7 and @entity319 (p=0.35, chi-square test). In survival analysis, neither the number of positive cells nor the staining intensity of both molecules was of prognostic significance. The expression of @entity7 and @entity319 in @entity1149 cells was confirmed in this study. The relation to clinical variables and survival will be further assessed in a larger group of @entity1 .

title: Expression of @entity7 ( @entity7 ) and its receptor @entity319 in XXXX ( @entity1149 )--a preliminary report.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['archival tumour', 'tumour']

answer: @entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']


abstract: UNASSIGNED: Despite the routine collection of oocytes from @entity1238 ( @entity1238 ) for use in research, few studies have evaluated methods for preparing their skin for surgery. We evaluated 3 skin preparatory agents by examining their antibacterial efficacy and the gross and microscopic appearance of @entity1238 skin after exposure. Frogs (n = 14) were sedated and treated (contact time, 10 min) with 0.9% sterile @entity4202 on one-half of the ventrum and with 0.5% @entity4279 or 0.75% @entity1216 on the other half. Bacterial cultures were obtained before and after skin treatment; bacteria were identified by mass spectrometry. To assess @entity32 and degenerative changes, the incision sites were photographed and biopsied at 0, 1, and 7 d after surgery. We isolated at least 22 genera of bacteria from the skin of our frog population (mean    SE, 5.21    0.82 genera per frog). @entity1496 (2.00    0.44 genera) and @entity1216 (0.29    0.76 genera) both had greater antimicrobial activity than did saline. Skin erythema did not correlate with treatment group. Histologic evidence of @entity528 and @entity39 was greater on days 1 and 7 after @entity1216 treatment than after @entity1496 or saline. In addition, frogs treated with @entity1216 had a higher incidence of clinical illness associated with the exposure site. In summary, although @entity1216 has adequate antimicrobial activity against organisms on @entity1238 skin, it leads to @entity272 and subsequent clinical complications. We therefore do not recommend @entity1216 as a preoperative preparation agent in @entity1238 .

title: Evaluation of Presurgical Skin Preparation Agents in @entity1238 ( XXXX ).

entities_list: @entity1216 :: ('MESH:D002710', 'Chemical') :: ['chlorhexidine']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity1496 :: ('MESH:D007455', 'Chemical') :: ['iodine', 'Iodine']

entities_list: @entity1238 :: ('8355', 'Species') :: ['African clawed frogs', 'Xenopus laevis', 'Xenopus', 'X. laevis']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity4279 :: ('MESH:D011206', 'Chemical') :: ['povidone-iodine']

entities_list: @entity272 :: ('MESH:D012871', 'Disease') :: ['skin damage']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['epidermal degeneration']

answer: @entity1238 :: (8355,Species) :: ['Xenopus laevis']


abstract: OBJECTIVE: Development of new custom-made devices to reconstruct alveolar bone for implantation, and comparison with conventional methods were the goals of this study. MATERIALS AND METHODS: Using a computer-aided design technique, three-dimensional images were constructed. From these data, custom-made devices were produced by a selective laser melting method with pure @entity702 . Clinical trials also have been conducted with 26 @entity1 who needed bone reconstruction before implantation; they were divided into 2 groups with 13 @entity1 each. The first group uses custom-made devices; the other uses commercial @entity702 meshes that need to bend during operation. Some clinical aspects are evaluated after the trial. RESULTS: The custom-made devices can be produced closely by following the data precisely. Devices are fit for bone defect site. Moreover, the operation time of the custom-made group (75.4      11.6  min) was significantly shorter than that of the conventional group (111.9      17.8  min) (p  <  0.01). @entity33 occurs, without significant difference (p  =  0.27), in a @entity1 in the custom-made without severe @entity281 (7.7%), and 3 in conventional (23.1%), respectively. The retaining screw is significantly fewer in the custom-made group than commercial mesh group (p  <  0.01). CONCLUSION: These results indicate that our novel protocol could be simple and safe for providing powerful support for guided bone regeneration.

title: Custom-made XXXX devices as membranes for bone augmentation in implant treatment: Clinical application and the comparison with conventional @entity702 mesh.

entities_list: @entity702 :: ('MESH:D014025', 'Chemical') :: ['titanium']

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'patient']

entities_list: @entity33 :: ('MESH:D052016', 'Disease') :: ['Mucosal rupture']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

answer: @entity702 :: (MESH:D014025,Chemical) :: ['titanium']


abstract: BACKGROUND: @entity1534 @entity1534 antimicrobial resistance is the most common reason for eradication failure. Small studies have shown @entity868 resistance to be more prevalent in certain population groups. AIM: To determine the resistance rates in a large cohort of @entity1 from a single centre in the UK, and to evaluate resistance patterns over time, according to age, sex and socio-economic status. METHODS: Consecutive @entity1 with @entity1534 -positive antral gastric biopsy samples were studied from 1994 to 1999. Susceptibility testing was performed to @entity868 , @entity803 , @entity7646 and @entity115 by the modified disk diffusion METHOD: The Jarman under-privileged area score was used as a measure of socio-economic status. RESULTS: A total of 1064 @entity1 were studied. Overall @entity868 resistance was 40.3%, decreasing with age (P < 0.0001, odds ratio for @entity1 over 60 years 0.63, 95% CI: 0.48-0.80). @entity1 were more likely to have @entity868 resistant strains (P=0.003, odds ratio 1.5, 95% CI: 1.15-1.91), but there was no association with Jarman score. @entity7646 resistance was associated with @entity868 resistance (P=0.03, odds ratio 2.14, 95% CI: 1.07-4.28). CONCLUSIONS: @entity868 resistance in @entity1534 is highly prevalent and more common in @entity1 and the young, but does not appear to be related to socio-economic status.

title: XXXX @entity1534 antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Women']

entities_list: @entity868 :: ('MESH:D008795', 'Chemical') :: ['metronidazole', 'Metronidazole']

entities_list: @entity115 :: ('MESH:D000658', 'Chemical') :: ['amoxicillin']

entities_list: @entity7646 :: ('CHEBI:25106', 'Chemical') :: ['macrolide', 'Macrolide']

entities_list: @entity1534 :: ('210', 'Species') :: ['pylori', 'H. pylori', 'Helicobacter']

entities_list: @entity803 :: ('MESH:D013752', 'Chemical') :: ['tetracycline']

answer: @entity1534 :: (210,Species) :: ['Helicobacter']


abstract: OBJECTIVE: To evaluate the long-term results of @entity1 surgically treated for metastatic @entity1358 ( @entity1358 ) with a unique pancreatic secondary localization to assess the importance of radical treatment in this rare group of @entity1 . @entity1 AND METHODS: This is a retrospective monocentric study including 20 surgically treated @entity1 between 1997 and 2012 for a unique pancreatic @entity3 of a @entity1358 . The main objective was to evaluate the outcome after surgical resection. RESULTS: Twenty @entity1 were followed up for a @entity1358 . The M/F ratio was 1.2. The average age of onset of @entity703 was 57.05    7.78  years. Two @entity1 who had synchronous pancreatic @entity3 and 18 @entity1 who had metachronous @entity3 appeared after an average of 130    59  months (24-240 months). The average size of the metastases was 20    11.6  mm. @entity788 was unique in all @entity1 , with 35% of @entity1 having multiple lesions of the pancreas. All @entity1 underwent a pancreatic resection of @entity3 . Histologic examination confirmed the location of a secondary @entity1358 in all @entity1 . Median follow-up after pancreatectomy was 69  months (1-150 months). Disease-free survival at 2  years was 60%. Overall survival rates at 2 and 4  years were 79% and 72%, respectively. There was no difference found between @entity1 with multiple and unique pancreatic metastases in overall survival. CONCLUSION: Unique pancreatic @entity3 of @entity1358 is rare. The literature on this subject is limited. Surgical resection might be an option and can be associated with long-term disease-free intervals in highly selected @entity1 .

title: XXXX from @entity1358 : outcome of an aggressive approach.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['Pancreatic metastasis']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['CCRCC', 'clear cell renal cell carcinoma']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity703 :: ('MESH:D007680', 'Disease') :: ['kidney cancer']

answer: @entity788 :: (MESH:D010190,Disease) :: ['Pancreatic metastasis']


abstract: Non @entity2067 antagonist oral anticoagulants (NOACs) have advantages relative to traditional @entity2067 antagonist oral anticoagulants and represents an important advance in the management of @entity1 with @entity955 and @entity1211 . Yet it is unclear whether the clinical trials evaluating these agents were inclusive of diverse populations. To assess the inclusion and reporting of race and ethnicity in clinical trials of NOACs across disease states including, @entity955 , @entity1211 , and @entity1187 , we queried PubMed and ClinicalTrials.gov for trials of NOACs between 2007 and 2013. We determined the reporting rate and inclusion of the following ethnic groups: whites, blacks, Asians, and Hispanics. We reviewed data from 30 randomized clinical trials of NOACs that enrolled 184,414 @entity1 . Among these trials, 21 (70  %) reported race/ethnicity data in the primary manuscript or on ClinicalTrials.gov. Principal investigators provided race/ethnicity data for two additional trials. Enrollment by race included: 109,729 (75.2  %) white, 20,901 (14.3  %) Asian, 5,718 (3.9  %) Hispanic, and 2,941 (2.0  %) black. Hispanic ethnicity was only reported in 10 trials. The major clinical trials of NOACs inconsistently reported race/ethnicity and overall black and Hispanic @entity1 enrollment was poor. As such, the relative safety and efficacy of NOACs in minority populations remains uncertain.

title: Review of race/ethnicity in non XXXX antagonist oral anticoagulants clinical trials.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1187 :: ('MESH:D054058', 'Disease') :: ['acute coronary syndromes']

entities_list: @entity2067 :: ('MESH:D014812', 'Chemical') :: ['vitamin K']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation']

entities_list: @entity1211 :: ('MESH:D054556', 'Disease') :: ['venous thromboembolism']

answer: @entity2067 :: (MESH:D014812,Chemical) :: ['vitamin K']


abstract: 1. The antagonism at alpha-adrenoceptors by @entity9005 and @entity5521 of the response to @entity1063 was investigated in the limb veins and arteries of @entity1 .2. Brachial artery infusions of @entity9005 (40 mug/min) produced rises in resting arterial flow of up to 100%. When infused mixed with @entity1063 , @entity9005 (40 mug/min) attenuated the blood flow response to @entity1063 . Blockade was of a similar degree to that which occurred following a 10 min infusion of @entity5521 (40 mug/min).3. Local intravenous infusion of @entity9005 (400-2,000 ng/min) mixed with @entity1063 attenuated the venoconstrictor response to @entity1063 . The degree of attenuation was similar to that seen after a 10 min infusion of @entity5521 (500 ng/min). Blockade after @entity9005 did not last longer than 16 minutes. Neither @entity9005 nor @entity5521 altered resting venous compliance.4. Local intravenous infusions of @entity9005 (500 ng/min) and @entity5521 (500 ng/min) abolished the sympathetically mediated venoconstriction produced by overbreathing.5. Systemic injection of @entity9005 (0.1 mg/kg) did not block the reduction in forearm arterial flow produced by locally infused @entity1063 . In two out of three experiments, however, it produced some antagonism of @entity1063 induced venoconstriction. Systemic @entity5521 (5 mg) blocked the effect of @entity1063 in the arterial bed, but antagonized its actions in the veins in only one out of three experiments.

title: Comparison of blockade at alpha-adrenoceptors by @entity9005 and @entity5521 in peripheral arteries and veins of XXXX .

entities_list: @entity9005 :: ('MESH:D013948', 'Chemical') :: ['thymoxamine']

entities_list: @entity1063 :: ('MESH:D009638', 'Chemical') :: ['noradrenaline']

entities_list: @entity5521 :: ('MESH:D010646', 'Chemical') :: ['phentolamine']

answer: @entity1 :: (9606,Species) :: ['man']


abstract: @entity5 growth is associated with @entity4795 , @entity1148 , and extramedullar hematopoiesis. The mechanism(s) accounting for these phenomena is unclear, although @entity2304 ( @entity2304 ) and/or @entity24778 ( @entity24778 ) released by @entity5 cells have been involved. We studied whether CSF released by @entity8270 ( @entity8270 ) may play a role. A comparative study was performed with two cell variants ( @entity8270 and @entity8270 /0) growing in euthymic, nude, and @entity915 @entity19 . Extramedullar hematopoiesis was assessed in the spleen by scoring organ enlargement, @entity3505 germ agglutinin ve+ cells, and interleukin 3-dependent granulocyte-macrophage colony-forming unit (GM-CFU). Both cell lines showed the same cytokine profile by reverse transcriptase polymerase chain reaction, including @entity2304 , @entity24778 , and @entity9827 ( @entity9827 ); yet, only @entity8270 cells produced detectable colony-stimulating activity in vitro, mainly due to @entity2304 . No differences in tumorigenicity were noted between @entity8270 and @entity8270 /0 cells inoculated to normal or @entity465 @entity19 . An increase in extramedullar hematopoiesis, accompanied by @entity4795 and @entity1148 , was associated with @entity5 progression irrespective of the cell line. A strong correlation was obtained between the increase in splenic GM-CFU and @entity5 mass (r = 0.96, p < 0.0001) that was independent on the @entity5 cell line, strain of @entity19 , or stage of @entity5 development. The results point against CSF released by @entity5 cells and/or reactive host T cells as the only factors involved in the extramedullar hematopoiesis in this @entity5 model. The remarkable correlation between @entity5 mass still suggests that a factor(s) of @entity5 origin may play a critical role.

title: XXXX stimulates extramedullar hematopoiesis in @entity19 without secreting identifiable colony-stimulating factors and without engagement of host T cells.

entities_list: @entity2304 :: ('12981(Tax:10090)', 'Gene') :: ['GM-CSF', 'granulocyte-macrophage colony-stimulating factor']

entities_list: @entity1148 :: ('MESH:D013922', 'Disease') :: ['thrombocytosis']

entities_list: @entity9827 :: ('12977(Tax:10090)', 'Gene') :: ['M-CSF', 'macrophage colony-stimulating factor']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'splenic GM-CFU and the tumor', 'Tumor']

entities_list: @entity24778 :: ('12985(Tax:10090)', 'Gene') :: ['G-CSF', 'granulocyte colony-stimulating factor']

entities_list: @entity465 :: ('MESH:D007153', 'Disease') :: ['immunodeficient']

entities_list: @entity4795 :: ('MESH:C563010', 'Disease') :: ['neutrophilia']

entities_list: @entity8270 :: ('MESH:D002286', 'Disease') :: ['ET', 'Ehrlich tumor']

answer: @entity8270 :: (MESH:D002286,Disease) :: ['Ehrlich tumor']


abstract: OBJECTIVE: Very few studies have examined post-operative morbidity after resection of @entity189 , especially in @entity1 treated with induction chemo- and radiotherapy for locally advanced stages. This study assessed the effects of induction chemoradiotherapy on post-operative course after resection of locally advanced @entity189 ( @entity15004 + cM1lymph). METHODS: Induction therapy consisted of @entity1487 days 1-5 and days 21-25, @entity900 day 1 + day 21 and concomitant radiotherapy 18-20 fractions of 2Gy (total dose 36-40Gy). Induction chemoradiotherapy was completed in 109 @entity1 . Surgery was performed in 90 @entity1 (operability: 90/109 = 83%): 85 @entity1 underwent resection with curative intent (resectability: 85/109 = 78%), bypass operation was performed in five @entity1 . Nineteen @entity1 could not be operated on. Results were compared to a matched group of pT3M1LYM/pT4 @entity1 (n = 86) who underwent primary surgery in the same period. RESULTS: Resection was complete (R0) in 68 @entity1 (68/90 = 76%). Mean duration of surgery was 428 min (range: 240-690). Peroperative complications were @entity548 in three @entity1 (3/90 = 3.3%), tracheobronchial perforation in three @entity1 (3/90 = 3.3%). Median total hospital stay was 20.5 days (range: 8-355). Mean duration of intubation was 7 days (range: 1-190); 67 @entity1 (67/90 = 74.4%) were intubated for less than 24 h. @entity5 related hospital mortality after resection was 8.3% (7/84 @entity1 ). Mortality after two-field lymphadenectomy was 5.2 versus 11.7% after three-field lymphadenectomy. After primary surgery (n = 86) overall mortality was 2.3% (P = 0.015) and nil after two- and three-field lymphadenectomy (P = 0.011). Medical morbidity consisted of @entity55 in 43 @entity1 (43/90 = 48%), @entity891 in ten @entity1 (10/90 = 11%), @entity943 in 21 @entity1 (21/90 = 23%), @entity295 in 11 @entity1 (11/90 = 12%) and adult @entity649 in ten @entity1 (10/90 = 11%). Surgical morbidity included @entity1143 in 16 @entity1 (16/90 = 18%), @entity292 in two @entity1 (2/90 = 2%), chylothorax in two @entity1 (2/90 = 2%) and acute @entity788 in one @entity1 (1/90 = 1%). Ten @entity1 (10/90 = 11%) had a radiologically confirmed @entity834 ; however only in four out of them with clinical manifestation; treatment was conservative in all four @entity1 . Major morbidity occurred in 27 @entity1 (27/90 = 30%). Overall rate of morbidity was significantly higher after three-field lymphadenectomy (85%) as compared to two-field lymphadenectomy (68.7%; P = 0.023). CONCLUSIONS: Chemoradiotherapy followed by resection of @entity15004 +/- cM1lymph @entity189 is feasible with acceptable mortality. Mortality, however, seems to be significantly higher when compared to a group of pT3M1LYM/pT4 @entity1 who underwent primary surgery (8.3 versus 2.3%; P = 0.015) in the same period in our department.

title: Effects of preoperative chemoradiotherapy on postsurgical morbidity and mortality in XXXX +/- cM1lymph cancer of the oesophagus and gastro-oesophageal junction.

entities_list: @entity1143 :: ('MESH:D010996', 'Disease') :: ['pleural effusion']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis']

entities_list: @entity834 :: ('MESH:D057868', 'Disease') :: ['anastomotic leak']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['haemorrhage']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Non-tumour']

entities_list: @entity649 :: ('MESH:D012128', 'Disease') :: ['respiratory distress syndrome']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['oesophageal carcinoma']

entities_list: @entity891 :: ('MESH:D001261', 'Disease') :: ['atelectasis']

entities_list: @entity292 :: ('MESH:D005402', 'Disease') :: ['tracheal fistula']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['dysrhythmia']

entities_list: @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-fluorouracil']

answer: @entity15004 :: (158809,Gene) :: ['cT3-4']


abstract: Hypericum perforatum L. (St. John's wort) is a medicinal plant used for many pathologies, especially for the treatment of mild to moderate @entity308 . In the present study we have investigated the cytotoxic activity of the locally collected (Epirus region) Hypericum perforatum L. against cultured @entity1 and @entity150 cell lines. The lipophilic extract of the herb, prepared using @entity8144 , induced apoptosis displaying LC(50) values at concentrations as low as 4 and 5 microg/mL. A fraction of this extract displayed 60 % cell growth inhibition at a concentration of 0.95 microg/mL. Evaluating the importance of various biologically active components of the extract, it was found that hypericins ( @entity19486 , @entity55882 , etc.) were identified only in the methanolic (lipophobic) extract of the herb, and not in the active lipophilic extract. In addition, @entity22738 concentrations in the lipophilic extract and its most active fraction, were 0.94 microg/mL, and 0.17 microg/mL, respectively, while the active cytotoxic concentration of pure hyperforin appeared in the range of 1.8 microg/mL - 5.0 microg/mL. Therefore, pure hyperforin does not seem to contribute significantly to the @entity137 activity. Chlorophylls were identified in low, not significantly different, concentrations in all extracts and fractions and were not correlated to the biological activity. Owing to the combination of significant cytotoxic activity, natural abundance and low @entity137 , the lipophilic extract of Hypericum perforatum holds the promise of being an interesting, new, antiproliferative agent against @entity150 that deserves further investigation.

title: The lipophilic extract of Hypericum perforatum exerts significant cytotoxic activity against @entity1 and NBT-II XXXX cells.

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity22738 :: ('MESH:C001654', 'Chemical') :: ['hyperforin']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'cytotoxicity']

entities_list: @entity8144 :: ('MESH:C004544', 'Chemical') :: ['petroleum ether']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['NBT-II bladder cancer', 'bladder cancer']

entities_list: @entity55882 :: ('MESH:C056602', 'Chemical') :: ['pseudohypericin']

entities_list: @entity19486 :: ('MESH:C004965', 'Chemical') :: ['hypericin']

answer: @entity150 :: (MESH:D001749,Disease) :: ['urinary bladder tumor']


abstract: This study was conducted in order to investigate the implications of the @entity7820 polymorphism in the @entity876 gene in @entity0 risk. The enlightenment of this matter might provide a piece of information about the potential implications of this polymorphism in @entity1 risk. A meta-analysis was conducted considering a large sample size from studies with conflicting results on the @entity7820 polymorphism in @entity0 @entity1 . Relevant studies were selected from PubMed and SciELO databases for data extraction and statistical analysis. Database was built according to the continent and considering the genotype frequencies, sample size and genotyping methodology. The dominant models (RR vs @entity6391 + PP and RR + @entity6391 vs. PP), homozygous (RR vs. PP), heterozygous (RR vs. @entity6391 and @entity6391 vs. PP) and the allele (R vs. P) were used. Genotype frequencies were summarized and evaluated by   (2) test of heterogeneity in 2*2 contingency tables with 95% CIs. Odds Ratios (OR) were calculated with a fixed-effect model (Mantel-Haenszel) or a random-effect model (DerSimonian-Laird) if the studies were considered homogeneous (P > 0.05) or heterogeneous (P < 0.05), respectively, using BioEstat   5.0 software. Supported by a large sample size composed by 25,629 cases and 26,633 controls from 41 studies, we found significant association between the @entity7820 polymorphism in the @entity876 gene and the @entity0 risk. The overall data shows an increased risk due to the P allele dominant model, but not in Asia where the risk was associated with the R allele and R dominant model.

title: Association of the XXXX codon 72 polymorphism and @entity0 risk: a meta-analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity7820 :: ('p|SUB|R|72|P', 'ProteinMutation') :: ['R72P']

answer: @entity876 :: (7157,Gene) :: ['TP53']


abstract: BACKGROUND: National registries are advocated as instrumental to the solution of rarity-related problems for @entity1 with @entity1121 ( @entity1121 ), including limited access to advanced treatment options. Thus, an Italian Registry for @entity1121 was created to assess the clinical profile and the level of care nationwide of @entity1 with @entity1121 . METHODS: Cardiology centers over the national territory were recruited to provide clinical data of all @entity1 with @entity1121 ever seen at each institution. The enrollment period was from May 2000 to May 2002. RESULTS: The registry enrolled 1677 @entity1 from 40 institutions. Most (69%) were followed at referral centers, whereas 31% were from community centers with intermediate-low @entity1 flow. @entity1 diagnosed after routine medical examinations or familial screenings were 39%. Most @entity1 were male (62%), in their fourth to sixth decade of life, and in New York Heart Association class I to II (89%); 24% had resting left @entity67 and 18% had @entity955 . During a 9.7-year average follow-up, cardiovascular mortality was 1%/y, mostly because of @entity712 , with no significant change over the last 3 decades; @entity944 was less common (0.4%/y). Only 4% of @entity1 received a defibrillator; 14% of the 401 @entity1 with LV outflow obstruction underwent invasive relief of obstruction; and <1% were offered genetic analyses or counseling. CONCLUSIONS: The Italian Registry represents the first comprehensive attempt to evaluate the clinical impact and management of @entity1121 at a national level. Findings underscore the role of screening strategies for an early diagnosis and suggest limited use of the advanced therapeutic options for @entity1121 .

title: The Italian Registry for XXXX : a nationwide survey.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure']

entities_list: @entity944 :: ('MESH:D003645', 'Disease') :: ['sudden death']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation']

entities_list: @entity67 :: ('MESH:D018754', 'Disease') :: ['ventricular obstruction']

entities_list: @entity1121 :: ('MESH:D002312', 'Disease') :: ['HCM', 'hypertrophic cardiomyopathy']

answer: @entity1121 :: (MESH:D002312,Disease) :: ['hypertrophic cardiomyopathy']


abstract: OBJECTIVE: Phyllodes @entity5 of the breast is a rare @entity0 that comprise 0.3-0.9% of primary @entity0 . In this study, we aimed to present clinicopathologic symptoms of our @entity1 along with their treatment modality. MATERIAL AND METHODS: Clinicopathologic properties and treatment modality of 20 phyllodes @entity5 @entity1 who underwent surgery between January 2008 and January 2013 were retrospectively evaluated. RESULTS: Median @entity1 age was 47 years (22-75). Fine-needle aspiration biopsy was applied to 19 @entity1 . Biopsy results were reported as suspicious in four, malignant in three, benign in 11, and as non-diagnostic in one @entity1 . Final histopathology reports revealed two benign, one malignant and one borderline @entity5 out of the four @entity1 with suspicious findings on fine needle aspiration biopsy; all @entity1 with malignant cytology had @entity5 . There were two borderline and nine benign lesions within the benign biopsy group. Sixteen @entity1 underwent segmental mastectomy, four @entity1 underwent mastectomy with/without axillary dissection. The median @entity5 size was 6 (1-13) cm. Histopathologically, 11 (55%) @entity5 were benign, 5 (25%) were borderline, and 4 (20%) were malignant. Two of the four @entity1 with @entity5 underwent radiotherapy and chemotherapy, and one @entity1 only received chemotherapy as adjuvant treatment. CONCLUSION: @entity5 are rare, mix-type @entity0 . Due to high rates of local recurrence and potential for @entity5 , preoperative diagnosis and accurate management are important.

title: How to approach phyllodes XXXX of the breast?

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Phyllodes tumors', 'malignancy', 'tumors']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['fibroepithelial breast tumor', 'breast tumors', 'breast neoplasms']

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumors']


abstract: OBJECTIVE: The study of personality pathology in adolescence is in its infancy. This article examined the applicability and limits of DSM-IV @entity1314 diagnoses in adolescents, assessed the validity of a method for assessing adolescent personality pathology, and began to develop an empirically grounded classification. METHOD: A total of 296 randomly selected clinicians described a @entity1 age 14-18 in treatment for @entity1314 patterns using @entity2270 II ratings scales and the Shedler-Westen Assessment Procedure-200 for Adolescents (SWAP-200-A), a Q-sort instrument for assessing adolescent personality pathology. After examining the nature and frequency of @entity74 in the sample, the authors used Q-factor analysis to identify naturally occurring groupings of @entity1 on the basis of shared personality features. RESULTS: Axis II diagnoses in adolescents resembled those in adults, although application of DSM-IV criteria appeared to overdiagnose antisocial and @entity1314 in adolescents. Q analysis with the SWAP-200-A isolated five @entity1314 (antisocial- @entity10420 , emotionally dysregulated, avoidant-constricted, narcissistic, and histrionic) and one personality style. @entity1 ' dimensional scores on each diagnostic prototype showed predictable associations with ratings of current @entity74 , measures of adaptive functioning, and symptoms assessed with the @entity1 Behavior Checklist. CONCLUSIONS: With some exceptions, personality pathology in adolescence resembles that in adults and is diagnosable in adolescents ages 14-18. Categories and criteria developed for adults may not be the optimal way of diagnosing adolescents. Data from samples of adolescents may prove useful in developing an empirically and clinically grounded classification of personality pathology in adolescents.

title: Personality diagnoses in adolescence: DSM-IV XXXX II diagnoses and an empirically derived alternative.

entities_list: @entity1 :: ('9606', 'Species') :: ['Child', 'Patients', 'patients', 'patient']

entities_list: @entity10420 :: ('MESH:D000987', 'Disease') :: ['psychopathic']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['axis II disorders']

entities_list: @entity1314 :: ('MESH:D010554', 'Disease') :: ['personality disorders', 'maladaptive personality', 'axis II personality disorder', 'avoidant personality disorder']

answer: @entity2270 :: (MESH:C566610,Disease) :: ['axis']


abstract: INTRODUCTION: The main objective of the study was to determine the frequency of @entity1 receiving inappropriate empiric antibiotic therapy and to assess the impact in terms of increase length of hospital stay, 30-day re-admissions, and 30-day mortality. METHODS: An observational retrospective cohort study was conducted over a one-month period that included all @entity1 hospitalised from an @entity341 ( @entity341 ) due to @entity281 . Demographic variables, comorbidity, multi-resistance risk factors, site of @entity281 , microbiological findings, and antibiotic prescribed in @entity341 were collected. Outcomes were length of hospital stay, 30-day re-admissions, and 30-day mortality. RESULTS: A total of 376 @entity1 were included, with a mean age of 71.1 (SD 21) years. The most frequent causes were respiratory (45.7%) and urine (23.9%) infections. The number of @entity1 with length of stay over the median (>= 9 days) was 165 (46.1%), with re-admissions 74 (19.7%), and mortality at 30 days 44 (11.7%). There was inappropriate antibiotic treatment in 42 (11.2%) cases. After adjusting for demographic data, comorbidity, risk factors for multidrug resistant organism, presence of @entity295 criteria in @entity341 , and site of @entity281 , inappropriate treatment was associated with an extended length of hospital stay (OR 2.22; 95% CI; 1.07-4.60; P=.032), but did not to an increase in mortality (P=.271) or re-admission (P=.784) at 30 days. CONCLUSION: The inappropriate empirical antibiotic therapy in @entity1 admitted from the @entity341 leads to an extended hospital stay, but did not increase mortality or readmission.

title: [Effect of the inadequacy of antibiotic therapy in the XXXX on hospital stays].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity341 :: ('MESH:D004630', 'Disease') :: ['ED', 'Emergency Department']

answer: @entity341 :: (MESH:D004630,Disease) :: ['Emergency Department']


abstract: When a @entity548 complication occurs during therapy with heparin or @entity2067 antagonists, there is an option to give a specific antidote. Several new anticoagulants have been developed that are likely to have some risk of @entity548 complications, for which no specific antidotes are available. Interestingly, it is unknown how often the use of an antidote is necessary in clinical practice. We investigated 1877 @entity1 treated for @entity1211 included in three large clinical trials, of which 181 (9.6%) had a total of 225 adjudicated @entity548 episodes; 46 @entity548 being designated as major. Some form of antidote was given to 26 (14.4%) @entity1 with a @entity548 . Of the @entity1 with at least one major @entity548 , 19 (41.3%) received an antidote. @entity2067 was given to 23 (1.2%) @entity1 , one (0.05%) @entity1 received protamin sulfate and seven (0.4%) @entity1 received fresh frozen plasma. The use of antidotes was comparable for initial and long-term treatment. Antidotes were statistically significantly more frequently given in Canada as compared to other participating countries. @entity2067 was more frequently given in case of a higher international normalized ratio value. Although antidotes against anticoagulant treatment are widely available, our analysis shows that in only a very small number of @entity1 a direct, or slow-acting antidote to reverse the anticoagulant effect was used.

title: The use of specific antidotes as a response to @entity548 complications during anticoagulant therapy for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1211 :: ('MESH:D054556', 'Disease') :: ['venous thromboembolism']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhages', 'hemorrhage', 'bleeding']

entities_list: @entity2067 :: ('MESH:D014812', 'Chemical') :: ['Vitamin K', 'vitamin K']

answer: @entity1211 :: (MESH:D054556,Disease) :: ['venous thromboembolism']


abstract: The growth behaviour of the probiotic strain @entity5259 . toyoi in the gastrointestinal tract of broiler @entity1573 and suckling piglets was evaluated. The strain germinated rapidly in intestinal samples from both animal species. Less than 10% of spores were recovered from the @entity1573 crop and piglet stomach, respectively. Lumen samples and mucosal tissues from the hind gut of piglets displayed increasing colonization of the probiotic strain throughout the trial period. After oral administration of vegetative cells to broiler @entity1573 and weaned piglets, sporulation was detected in all intestinal samples. The distribution of spore CFU indicated repeated germination and sporulation during the intestinal passage in piglets. @entity5259 . toyoi was not able to colonize the intestinal tract of both animal species. However, the probiotic strain was detected in suckling piglets before uptake of @entity5259 . toyoi supplemented feed. It is concluded that @entity5259 . toyoi germinates rapidly in broiler @entity1573 and piglets, which is a necessary prerequisite for its possible probiotic effects. Germination and in vivo sporulation of vegetative cells indicated that the probiotic strain was metabolically active in the intestine of both animal species.

title: Growth behaviour of a spore forming probiotic strain in the gastrointestinal tract of broiler XXXX and piglets.

entities_list: @entity5259 :: ('1396', 'Species') :: ['B. cereus var', 'Bacillus cereus var']

answer: @entity1573 :: (9031,Species) :: ['chicken']


abstract: An 163-bp fragment of the @entity35 cytochrome P450 gene, @entity51714 has been shown to contain sequences that mediate @entity109 (PB) responsiveness of this gene. In studies on this @entity35 gene and the orthologous @entity19 gene, @entity5795 , the minimal fragment required for near full PB responsiveness has varied from about 50 to 80 bp depending on the gene used and the number of copies of the PB responsive sequences assessed. Since there is a single copy of the CYP genes in the genome, we have evaluated deletion and block mutations across an 84-bp region of the PB responsive unit (PBRU), by in situ transfection in @entity35 liver using single copies of the PBRU sequences. From the 5' end, deletions to -2243 retained more than 50% responsiveness to PB compared to the 163-bp fragment. The fragment -2237 to -2155 retained less than 20% responsiveness even though it contained the nuclear receptor (NR)-1, NR-2, and NF-1 motifs which are present in the core of the PBRU. From the 3' end, deletions from -2170 to -2194 eliminated PB responsiveness indicating that the 74-bp sequence from -2243 to -2170 is able to mediate full PB responsiveness. Block mutations within the @entity4474 and NF-1 regions reduced responsiveness most dramatically, but did not abolish it, and mutations 3' of the NF-1 site modestly reduced responsiveness. Protein binding was not affected by mutations in the @entity4474 region as assessed by @entity3420 footprinting in vitro but mutations within the NR-2 region reduced binding to the NF-1 site. Mutations of the 5' half or the 3' half of the bipartite NF-1 site, resulted in loss of protection of the NF-1 site and new footprints to the 3' or 5' side, respectively, of the NF-1 site. These results indicate that sequences in addition to the @entity4474 and the NF-1 sites are required for full responsiveness to PB and suggest that proteins which bind to these sites may interact.

title: Functional analysis of the @entity109 -responsive unit in @entity35 XXXX .

entities_list: @entity109 :: ('MESH:D010634', 'Chemical') :: ['phenobarbital']

answer: @entity51714 :: (361523(Tax:10116),Gene) :: ['CYP2B2']


abstract: UNASSIGNED: @entity692 (HA)-coated @entity3703 nanoparticles (MNPs) are being widely investigated for various applications in medical engineering and wastewater treatment. In this work, the MNPs were thoroughly coated by bacterial synthesized HA nanoparticles during biomineralization process using @entity9238 . The resulting bacterial-induced precipitate was then calcined at 600  C and investigated with respect to structural characteristics, particle size and magnetic strength by XRD, FT-IR, SEM, @entity15354 , TEM and VSM analyses. The effects of MNPs and HA-coated MNPs (HA-MNPs) on the viability of @entity1 MCF-7 cell lines were also investigated via mitochondrial activity test (MTT) and @entity880 dehydrogenase (LDH) assays. The powder characterization results showed appropriate structural properties for HA-MNPs samples. The particles diameter size of the MNPs and HA-MNPs were in the range of 3-25nm and 20-80nm, respectively. The biologically-synthesized HA-MNPs formed a stable suspension in water while keeping their magnetic property. The saturation magnetization (Ms) of HA-MNPs was measured at ~10emug(-1) which was in good agreement with the structural composition of this sample. Finally, the results of the cell lines viability indicated that coating of toxic MNPs via biomineralization was a promising approach in order to synthesize bio-compatible magnetic nanoparticles with suitable physical and chemical structural characteristics. The @entity137 level of MNPs was reduced by 10 fold when coated by bacterial-synthesized HA.

title: A biological method for in-situ synthesis of @entity692 -coated @entity3703 nanoparticles using @entity9238 : Characterization and acute XXXX assessments.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity9238 :: ('548', 'Species') :: ['Enterobacter aerogenes']

entities_list: @entity3703 :: ('MESH:D052203', 'Chemical') :: ['magnetite']

entities_list: @entity692 :: ('MESH:D017886', 'Chemical') :: ['Hydroxyapatite']

entities_list: @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate']

answer: @entity137 :: (MESH:D064420,Disease) :: ['toxicity']


abstract: UNASSIGNED: High grade serous @entity43 (HGSC) is a DNA instable @entity5 and its precursor is commonly found originating from the fimbriated end of the @entity5274 ( @entity5274 ) cells. The local stresses via ovulation and related @entity32 are risks for HGSC. In this study, we examined the cellular and molecular responses of @entity5274 cells to stress. We found that excess intracellular reactive @entity26 species (ROS) in normal @entity5274 cells upregulated a subset of microRNA expression (defined as ROSmiRs). Most ROSmiRs' expression and function were influenced and regulated by @entity876 , and together they drove the cells into @entity1642 ( @entity1642 ). However, ROS-induced @entity21175 is regulated by @entity3546 , not by @entity876 . In normal @entity5274 cells, @entity21175 overexpression triggers cellular senescence by @entity876 -mediated upregulation of @entity3544 . Conversely, in cells with @entity876 mutations, @entity21175 overexpression no longer enhances @entity3544 but functions as an "Onco-miR". @entity876 dysfunction is a prerequisite for @entity21175 -mediated tumorigenesis. In addition, we found that @entity1 follicular fluid could significantly induce intracellular ROS in normal @entity5274 cells. These findings suggest that ROS and @entity876 mutations may trigger a series of events, beginning with overexpressing @entity21175 by ROS and @entity3546 , impairing the DNA damage response, promoting DNA instability, bypassing senescence and eventually leading to DNA instable @entity5 in @entity5274 cells.

title: Role of @entity21175 in response to oxidative stress in the cell fate of XXXX fallopian tube epithelial cells.

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian carcinoma']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity5274 :: ('MESH:D005184', 'Disease') :: ['fallopian tube secretory epithelial', 'FTSE']

entities_list: @entity1642 :: ('MESH:D015775', 'Disease') :: ['SIPS', 'stress-induced premature senescence']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: OBJECTIVE: To develop criteria for the classification of @entity15835 ( @entity15835 ) in @entity1 with @entity4932 ( @entity4932 ). METHODS: A multistep process, based on a combination of expert consensus and analysis of real @entity1 data, was conducted. A panel of 28 experts was first asked to classify 428 @entity1 profiles as having or not having @entity15835 , based on clinical and laboratory features at the time of disease onset. The 428 profiles comprised 161 @entity1 with systemic @entity4932 -associated @entity15835 and 267 @entity1 with a condition that could potentially be confused with @entity15835 (active systemic @entity4932 without evidence of @entity15835 , or @entity281 ). Next, the ability of candidate criteria to classify individual @entity1 as having @entity15835 or not having @entity15835 was assessed by evaluating the agreement between the classification yielded using the criteria and the consensus classification of the experts. The final criteria were selected in a consensus conference. RESULTS: Experts achieved consensus on the classification of 391 of the 428 @entity1 profiles (91.4%). A total of 982 candidate criteria were tested statistically. The 37 best-performing criteria and 8 criteria obtained from the literature were evaluated at the consensus conference. During the conference, 82% consensus among experts was reached on the final @entity15835 classification criteria. In validation analyses, these criteria had a sensitivity of 0.73 and a specificity of 0.99. Agreement between the classification ( @entity15835 or not @entity15835 ) obtained using the criteria and the original diagnosis made by the treating physician was high (k   =   0.76). CONCLUSION: We have developed a set of classification criteria for @entity15835 complicating systemic @entity4932 and provided preliminary evidence of its validity. Use of these criteria will potentially improve understanding of @entity15835 in systemic @entity4932 and enhance efforts to discover effective therapies, by ensuring appropriate @entity1 enrollment in studies.

title: 2016 Classification Criteria for Macrophage Activation Syndrome Complicating XXXX : A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['systemic infection']

entities_list: @entity15835 :: ('MESH:D055501', 'Disease') :: ['macrophage activation syndrome', 'MAS']

entities_list: @entity4932 :: ('MESH:D001171', 'Disease') :: ['JIA', 'systemic juvenile idiopathic arthritis']

answer: @entity4932 :: (MESH:D001171,Disease) :: ['Systemic Juvenile Idiopathic Arthritis']


abstract: UNASSIGNED: 7132 Background: We hypothesized that @entity2816 improves the response and @entity137 profile of chemotherapy with @entity3003 and @entity2600 because of its novel mechanism of action (anti-angiogenic, anti-neoplastic, anti-inflammatory) which is different from classic chemotherapy and because it causes @entity1142 which may counteract @entity294 of @entity2600 . METHODS: Treatment consists of @entity3003 AUC = 5 iv over 30 min day 1 and @entity2600 50 mg/m(2) iv over 90 min day 1 and 8 q 21 days. @entity2816 is given continuously po qhs starting on day 1 until progressive disease; the starting dose is 200 mg/d which is escalated by 100 mg per week if tolerated (max. 1,000 mg/d). The objectives are to determine the response rate, time to progression, overall survival, and @entity137 profile. Key eligibility criteria: @entity1149 stage IIIB ( @entity3483 ) and IV; measurable disease; no prior chemotherapy; prior radiation only allowed for brain @entity3 , neurologically stable; performance status (PS) 0-1; adequate hematologic, hepatic and renal function. RESULTS: So far, 36 @entity1 have been entered, but 2 never received protocol treatment; characteristics of 34 treated @entity1 : median age 65 (47-79); female/male 8/26; black/white 2/32; PS 0/1 in 10/24; stage 3/4 in 6/28. 23 @entity1 are evaluable for response: partial 5 (22%), stable 12 (52%). The median time to progression is 3.6 months (95% CI, 2.3-4.9). 19 of 34 @entity1 have died. The median survival time is 7.3 months (95% CI, 3.4-14.2). Frequent @entity137 are @entity1398 (grade 3/4 in 20%/8%), @entity1295 /malaise (grade 3/4 in 16%/4%), and @entity390 /vomiting (grade 3/4 in 20%/0%). @entity294 grade 3/4 occurred in 4%/4%. No @entity1 had lethal @entity137 . CONCLUSIONS: Treatment with @entity3003 , @entity2600 , and @entity2816 on this regimen is tolerable with reversible @entity1398 as the major @entity137 . Accrual to this study continues to more firmly establish the objective response rate and survival time. *Supported by NCI grant U10CA81851-04 [Table: see text].

title: Phase II study of @entity3003 , @entity2600 , and XXXX in @entity1 with advanced @entity1149 ( @entity1149 ).

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan']

entities_list: @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea', 'Diarrhea']

entities_list: @entity2816 :: ('MESH:D013792', 'Chemical') :: ['Thalidomide', 'thalidomide']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity3483 :: ('MESH:D016066', 'Disease') :: ['malignant pleural effusion']

entities_list: @entity1142 :: ('MESH:D003248', 'Disease') :: ['constipation']

answer: @entity2816 :: (MESH:D013792,Chemical) :: ['thalidomide']


abstract: PURPOSE: To investigate the incidence of @entity2118 induced by latanoprost ophthalmic solution in Japanese @entity726 @entity1 by a prospective and observer-masked study. @entity1 AND METHODS: Sixty-nine eyes of 69 @entity726 @entity1 were included. @entity1 who had undergone intraocular surgery, laser trabeculoplasty, and laser iridotomy within 12 months before enrollment, and @entity1 with history of @entity1596 and any changes in antiglaucoma drugs within 6 months before enrollment were excluded. Iridial photographs were taken by one examiner under the same conditions at 1, 3, and 6 months after the initiation of latanoprost treatment. Three @entity726 specialists, masked of @entity1 information, independently assessed the @entity2118 . Cases with @entity2118 diagnosed by three specialists were categorized as showing a definite increase in @entity2118 . RESULTS: A definite increase in @entity2118 occurred in 3.5%, 9.7%, and 35.0% of eyes within 1, 3, and 6 months of treatment, respectively. Age, gender, or concomitantly used eyedrops did not significantly influence the incidence of @entity2118 within 6 months of instillation. A reduction of intraocular pressure by latanoprost did not differ significantly between @entity1 with and without @entity2118 . CONCLUSION: The incidence of @entity2118 by latanoprost ophthalmic solution in Japanese @entity1 was higher than previously reported values in pigmented races.

title: Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese XXXX @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS']

entities_list: @entity2118 :: ('MESH:D010859', 'Disease') :: ['iridial pigmentation']

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma']

answer: @entity726 :: (MESH:D005901,Disease) :: ['glaucoma']


abstract: Morgagni-Larrey's @entity547 , which are both infrequent and generally asymptomatic, are often diagnosed by chance during routine diagnostic tests performed for other pathologies. Usually congenital in adults, they are often small or only take the form of a @entity362 . @entity432 is rarely described and frequently entails diagnostic difficulties before hydroaerial levels are demonstrated in the thoracic region. In these cases, surgery using an abdominal approach should be preferred in order to treat compressed abdominal viscera at the same time and to exclude the bilateral nature of the lesion. The authors present two cases of an adult @entity1 and @entity1 who were referred to their attention for occlusive pathologies. Both were operated using a laparotomy approach. The reduction of abdominal viscera did not present any difficulties. The hernial sac was only removed in the first @entity1 . Plastic surgery was completed by attaching the diaphragmatic flap to the costal and sternal wall using separate non-reabsorbing suture stitches. No complications were reported.

title: [ XXXX caused by Morgagni-Larrey diaphragmatic hernia].

entities_list: @entity362 :: ('MESH:D008067', 'Disease') :: ['pre-hernia lipoma']

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient', 'man']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['Intestinal occlusion']

answer: @entity432 :: (MESH:D001157,Disease) :: ['Intestinal occlusion']


abstract: BACKGROUND: @entity254 ( @entity254 ) is an innovative technique of pelvic dissection for low @entity5 . Our objective was to evaluate our pilot experience with this procedure compared with @entity1538 ( @entity1538 ). METHODS: We performed a retrospective 5-year review of all consecutive cases of @entity254 and @entity1538 performed at our institute. We focused on @entity5 characteristics, quality of surgery, analgesic requirements, average length of hospital stay (LOS), complications and long-term outcomes. RESULTS: Three @entity1 underwent @entity254 and 25 had @entity1538 . The average duration of surgery was similar (288 min for @entity254 v. 285 min for @entity1538 ). Four @entity1 in the @entity1538 group had positive or very close margins, and 2 had a mesorectal defect less than 5 mm. The average LOS was 6.66 and 9.29 days in the @entity254 and @entity1538 groups, respectively, and the average duration of epidural or @entity1 -controlled anesthesia was 2.67 and 5.16 days, respectively. We did not perform a statistical comparison because of the discordant size and sex distribution between the groups. There were no perioperative complications in the @entity254 group, and all @entity1 had negative margins and adequate lymph node retrievals with no long-term complications or recurrence recorded so far. CONCLUSION: Our very early experience with @entity254 is quite encouraging, suggesting that it is a safe alternative to @entity1538 with a similar duration and the added benefits of a minimally invasive procedure, including decreased LOS and reduced postoperative analgesic requirements.

title: Evaluation of pilot experience with robotic-assisted proctectomy and coloanal XXXX for @entity5 .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['rectal cancer', 'tumour']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity254 :: ('MESH:C563598', 'Disease') :: ['Robotic-assisted proctectomy with coloanal anastomosis', 'RPCA']

entities_list: @entity1538 :: ('MESH:D005902', 'Disease') :: ['open proctectomy with coloanal anastomosis', 'OPCA']

answer: @entity254 :: (MESH:C563598,Disease) :: ['anastomosis']


abstract: INTRODUCTION AND OBJECTIVE: Reendothelization of damaged blood vessels protects against the @entity1317 response. We evaluated in vivo whether a systemic increase in @entity268 accelerates reendothelization and attenuates intimal @entity1373 in injured @entity1707 carotid and coronary arteries. METHODS: Both carotid arteries of 10 @entity1707 were subjected to @entity130 . Five animals had been treated with 2 ml (10 mg) of @entity1928 , an activator of the adenylate cyclase, and another 5 with 2 ml of saline solution. These animals were sacrificed at day 8, and carotid artery reendothelization was evaluated. The descendent coronary (DC) artery of another 19 @entity1707 was injured by atherotome. Nine animals had been treated with 2 ml of @entity1928 , and another 10 with 2 ml of saline solution. These animals were sacrificed at day 28, with myointimal proliferation and arterial geometric remodelation being evaluated. Likewise, in these animals intracellular @entity268 levels were measured at baseline and 28 and 60 minutes after saline solution or @entity1928 administration and 90 min after @entity1317 . RESULTS: Eight days after @entity130 , carotid artery reendothelization was greater in the @entity1928 -treated group compared with the control group (p = 0.02), and the number of @entity24886 positive cells was statistically increased in the treated group (38 +/- 11 cells) versus controls (11 +/- 9 cells). Although the degree of @entity1317 caused by atherotome was similar in all of the arteries in the control group, restenosis was only observed in 40% of these animals. Correlation analysis demonstrated that intracellular @entity268 may condition arterial geometric remodeling and the diameter of the lumen after @entity1317 . CONCLUSION: Our results suggest that @entity268 may promote reendothelization and attenuate fibromuscular proliferation.

title: [Effect of XXXX on the function of endothelial cells and fibromuscular proliferation after the injury of the carotid and coronary arteries in a porcine model].

entities_list: @entity1373 :: ('MESH:D006965', 'Disease') :: ['hyperplasia']

entities_list: @entity1928 :: ('MESH:D005576', 'Chemical') :: ['Forskolin']

entities_list: @entity1317 :: ('MESH:D057772', 'Disease') :: ['vascular injury', 'arterial injury']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['balloon injury']

answer: @entity268 :: (CHEBI:17489,Chemical) :: ['cAMP']


abstract: BACKGROUND: Neutrophil-lymphocyte ratio (NLR) has been shown to be associated with prognosis in various solid @entity5 . This study aimed to evaluate the prognostic role of NLR in @entity1 with @entity957 ( @entity957 ). METHODS: A total of 141 @entity957 @entity1 were retrospectively reviewed. @entity1 ' demographics were analyzed along with clinical and pathologic data. The optimal cutoff value of NLR was determined using receiver operating characteristic (ROC) curve analysis. The impact of the NLR and other potential prognostic factors on disease-free survival (DFS) and @entity1349 ( @entity1349 ) was assessed using the Kaplan-Meier method and multivariate Cox regression analysis. RESULTS: The optimal cutoff value of the NLR was 2.17. In the NLR    <=   2.17 group, the 1-, 3-, and 5-year DFS rates were 88.2, 73.9 and 69.1  %, respectively, while in the NLR   >   2.17 group, the DFS rates were 83.0, 54.6 and 49.2  %, respectively. Correspondingly, the 1-, 3-, and 5-year @entity1349 rates were 98.9, 85.1 and 77.4  % in the NLR    <=   2.17 group and 97.9, 63.8 and 53.3  % in the NLR   >   2.17 group, respectively. The multivariate Cox proportional hazard model analysis showed that NLR   >   2.17 was a prognostic factor for both DFS [hazard ratio (HR)   =   1.869; 95  % confidence interval (CI) 1.078-3.243; P   =   0.026] and @entity1349 (HR =2.177; 95  % CI 1.208-3.924; P   =   0.010). CONCLUSION: Our results showed that elevated preoperative NLR was an independent predictor of poor prognosis for @entity1 with @entity957 after surgical resection.

title: Preoperative neutrophil-to-lymphocyte ratio is an independent prognostic marker in XXXX with @entity957 .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['LSCC', 'laryngeal squamous cell carcinoma']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: The Overall Nutritional Quality Index (ONQI) algorithm is a nutrient profiling scheme that incorporates more than 30 dietary components, and it aims to rank foods by relative healthfulness. PURPOSE: To assess whether diets with a higher ONQI score predict lower risk of major @entity102 risk. METHODS: A total of 62,284 healthy @entity1 from the Nurses' Health Study and 42,382 healthy @entity1 from Health Professionals Follow-Up Study were followed from 1986 to 2006. Dietary data were collected from questionnaires at baseline. Each food was scored by the ONQI algorithm and the average ONQI score for the diet consumed by each @entity1 was computed. @entity102 was defined as @entity65 ( @entity65 ); @entity5 ; @entity6 ; and nontrauma @entity204 . Data analysis was conducted in 2010. RESULTS: A total of 20,004 and 13,520 @entity102 events were documented in @entity1 and @entity1 , respectively. The ONQI score was inversely associated with risk of @entity102 , @entity65 , @entity6 , and all-cause mortality (p-trend <=0.01), but not @entity5 , in both cohorts. @entity1 in the highest compared to lowest quintile of the ONQI score had a relative risk (95% CI) of 0.91 (0.87, 0.95) for @entity102 ; 0.79 (0.71, 0.88) for @entity65 ; 0.86 (0.78, 0.96) for @entity6 ; and 0.90 (0.84, 0.97) for all-cause mortality. @entity1 in the highest compared to lowest quintile of the ONQI score had a relative risk of 0.88 (0.83, 0.93) for @entity102 ; 0.77 (0.70, 0.85) for @entity65 ; 0.84 (0.73, 0.96) for @entity6 ; and 0.89 (0.83, 0.97) for all-cause mortality. CONCLUSIONS: Consumption of foods that lead to a higher score for the ONQI scoring system is associated with modestly lower risk of @entity102 and all-cause mortality.

title: The association between a nutritional quality index and risk of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'participant', 'Women', 'Men', 'men']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic disease', 'total chronic disease', 'Total chronic disease']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['CVD', 'cardiovascular disease']

answer: @entity102 :: (MESH:D002908,Disease) :: ['chronic disease']